Tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for locally advanced/metastatic nonsquamous NSCLC
POSTER 09/2020
For more information about this resource, please submit a medical information request.
PD-1 inhibitor tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for locally advanced/metastatic nonsquamous NSCLC
Rating
